Complex evolutionary trajectories in vivo of two novel KPC variants conferring ceftazidime-avibactam resistance

IF 4.9 2区 医学 Q1 INFECTIOUS DISEASES International Journal of Antimicrobial Agents Pub Date : 2024-07-03 DOI:10.1016/j.ijantimicag.2024.107265
{"title":"Complex evolutionary trajectories in vivo of two novel KPC variants conferring ceftazidime-avibactam resistance","authors":"","doi":"10.1016/j.ijantimicag.2024.107265","DOIUrl":null,"url":null,"abstract":"<div><p>More and more ceftazidime-avibactam-resistant KPC-producing <em>Klebsiella pneumoniae</em> have been reported with its widespread use, and the detection rate of KPC variants has increased dramatically. However, the evolutionary mechanism and fitness effects during KPC mutation remained unknown. Here, we report the complex in vivo evolutionary trajectories of two novel KPC variants, KPC-155 (L169P/GT242A) and KPC-185 (D179Y/GT242A), from <em>K. pneumoniae</em> in the same patient. The novel variants were shown to confer ceftazidime-avibactam resistance but restore carbapenem susceptibility based on the results of plasmid transformation assays, cloning experiments, and enzyme kinetic measurements. In vitro, competition experiments highlighted the adaptive advantage conferred by strains carrying these KPC variants, which could lead to the rapid spread of these ceftazidime-avibactam-resistant strains. The growth curve indicated that <em>bla</em><sub>KPC-185</sub> had better growth conditions at lower avibactam concentration compared to <em>bla</em><sub>KPC-155</sub>, which was consistent with ceftazidime-avibactam use in vivo. In addition, replicative transposition of the IS<em>26</em>-flanked translocatable unit (IS<em>26</em>-IS<em>Kpn6</em>-<em>bla</em><sub>KPC</sub>-IS<em>Kpn27</em>-IS<em>26</em>) also contributes to the <em>bla</em><sub>KPC</sub> amplification and formation of two copies (<em>bla</em><sub>KPC-2</sub> and <em>bla</em><sub>KPC-185</sub>), conferring both carbapenem and ceftazidime-avibactam resistance. However, strains with double copies showed reduced competitive advantage and configuration stability. The comparative plasmid analysis of IS<em>26</em> group (IS<em>26</em>-<em>bla</em><sub>KPC</sub>-IS<em>26</em>) and Tn1721 group (Tn<em>1721</em>-<em>bla</em><sub>KPC</sub>-IS<em>26</em>) revealed that IS<em>26</em>-insertion could influence the distribution of resistance genes and ability of self-conjugation. The dynamic changes in <em>bla</em><sub>KPC</sub> configuration highlight the need for consistent monitoring including antimicrobial susceptibility testing and determination of <em>bla</em><sub>KPC</sub> subtypes – during clinical treatment, especially when ceftazidime-avibactam is administered.</p></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":null,"pages":null},"PeriodicalIF":4.9000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Antimicrobial Agents","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924857924001833","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

More and more ceftazidime-avibactam-resistant KPC-producing Klebsiella pneumoniae have been reported with its widespread use, and the detection rate of KPC variants has increased dramatically. However, the evolutionary mechanism and fitness effects during KPC mutation remained unknown. Here, we report the complex in vivo evolutionary trajectories of two novel KPC variants, KPC-155 (L169P/GT242A) and KPC-185 (D179Y/GT242A), from K. pneumoniae in the same patient. The novel variants were shown to confer ceftazidime-avibactam resistance but restore carbapenem susceptibility based on the results of plasmid transformation assays, cloning experiments, and enzyme kinetic measurements. In vitro, competition experiments highlighted the adaptive advantage conferred by strains carrying these KPC variants, which could lead to the rapid spread of these ceftazidime-avibactam-resistant strains. The growth curve indicated that blaKPC-185 had better growth conditions at lower avibactam concentration compared to blaKPC-155, which was consistent with ceftazidime-avibactam use in vivo. In addition, replicative transposition of the IS26-flanked translocatable unit (IS26-ISKpn6-blaKPC-ISKpn27-IS26) also contributes to the blaKPC amplification and formation of two copies (blaKPC-2 and blaKPC-185), conferring both carbapenem and ceftazidime-avibactam resistance. However, strains with double copies showed reduced competitive advantage and configuration stability. The comparative plasmid analysis of IS26 group (IS26-blaKPC-IS26) and Tn1721 group (Tn1721-blaKPC-IS26) revealed that IS26-insertion could influence the distribution of resistance genes and ability of self-conjugation. The dynamic changes in blaKPC configuration highlight the need for consistent monitoring including antimicrobial susceptibility testing and determination of blaKPC subtypes – during clinical treatment, especially when ceftazidime-avibactam is administered.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
赋予头孢他啶-阿维巴坦耐药性的两种新型 KPC 变体在体内的复杂进化轨迹。
随着头孢他啶-阿维菌素的广泛使用,越来越多产头孢他啶-阿维菌素耐药的肺炎克菌被报道,KPC变异株的检出率也急剧上升。然而,KPC变异过程中的进化机制和适应性效应仍然未知。在此,我们报告了来自同一患者肺炎克雷伯菌的两个新型 KPC 变体 KPC-155 (L169P/GT242A) 和 KPC-185 (D179Y/GT242A)的复杂体内进化轨迹。根据质粒转化实验、克隆实验和酶动力学测定的结果显示,这些新型变体具有头孢他啶-阿维菌素耐药性,但恢复了对碳青霉烯类的敏感性。体外竞争实验凸显了携带这些 KPC 变体的菌株所具有的适应优势,这可能会导致这些头孢他啶-阿维菌素耐药菌株的快速扩散。生长曲线表明,与 blaKPC-155 相比,blaKPC-185 在较低阿维巴坦浓度下的生长条件更好,这与头孢他啶-阿维巴坦在体内的使用情况一致。此外,IS26侧翼易位单元(IS26-ISKpn6-blaKPC-ISKpn27-IS26)的复制转位也导致了 blaKPC 的扩增并形成了两个拷贝(blaKPC-2 和 blaKPC-185),从而赋予了碳青霉烯类和头孢他啶类阿维巴坦的抗性。然而,具有双拷贝的菌株竞争优势和配置稳定性都有所下降。对 IS26 组(IS26-blaKPC-IS26)和 Tn1721 组(Tn1721-blaKPC-IS26)质粒的比较分析表明,IS26 插入会影响抗性基因的分布和自我结合能力。blaKPC 配置的动态变化突出表明,在临床治疗过程中,尤其是在使用头孢他啶-阿维巴坦时,需要进行持续监测,包括抗菌药物药敏试验和 blaKPC 亚型的确定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
21.60
自引率
0.90%
发文量
176
审稿时长
36 days
期刊介绍: The International Journal of Antimicrobial Agents is a peer-reviewed publication offering comprehensive and current reference information on the physical, pharmacological, in vitro, and clinical properties of individual antimicrobial agents, covering antiviral, antiparasitic, antibacterial, and antifungal agents. The journal not only communicates new trends and developments through authoritative review articles but also addresses the critical issue of antimicrobial resistance, both in hospital and community settings. Published content includes solicited reviews by leading experts and high-quality original research papers in the specified fields.
期刊最新文献
Access to phage therapy at Hospices Civils de Lyon in 2022: Implementation of the PHAGEinLYON Clinic program. Title Page & Editorial Board Hypervirulent Carbapenem-Susceptible Klebsiella pneumoniae ST412/K57 with Strong Biofilm Formation: association with gas gangrene and sepsis. Isoniazid Prophylaxis Based on Tuberculosis Risk Factors in Living Kidney Transplantation Recipients: A Retrospective Cohort Study. Machine Learning Accelerates the Discovery of Epitope-based Dual-bioactive Peptides Against Skin Infections.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1